Procyon Advisors LLC increased its holdings in Eli Lilly and Company by 176.8% in Q4, now owning shares worth $7.77 million. This comes amid positive developments for Eli Lilly, including promising drug trial results for obesity and pediatric treatments, and several analyst upgrades with price targets above $1,200. Despite some competitive and safety concerns, Eli Lilly reported strong quarterly earnings beating estimates and raised its 2026 guidance. Institutional investors hold over 82% of the stock, reflecting confidence in the company's long-term growth potential.
Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, gaining access to experimental drugs targeting mental health conditions like treatment-resistant depression. AtaiBeckley's lead drug, a DMT-based nasal sp...
Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...
